All In Biotech

Drug Trial Radar · NCT04077463

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

701

Actual

Start

Sep 4, 2019

Primary completion

Feb 12, 2027

Study completion Mar 27, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (JNJ-61186372) (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced non-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B, C, D and E), to estimate the antitumor activity of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC with documented advanced or metastatic EGFR mutation (Phase 1b expansion cohorts A, B, C, and D), to validate the biomarker identified in Phase 1b expansion Cohort D as a predictor of antitumor activity of Lazertinib and Amivantamab combination (Cohort E) or Amivantamab monotherapy (Cohort F) in participants with osimertinib-relapsed, chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC, to identify the recommended Phase 2 dose (RP2ChD) of Lazertinib when combined with Amivantamab and standard of care chemotherapy and to determine the tolerability of the Lazertinib, Amivantamab, and platinum-doublet chemotherapy (LACP) combination (Phase 1b LACP combination cohort) and to characterize the safety and tolerability of Lazertinib at the RP2ChD and Amivantamab and standard of care chemotherapy in participants with advanced or metastatic EGFR-mutated NSCLC (Phase 1b LACP combination cohort), to assess 2 potential biomarker strategies to identify participants at increased, or decreased, probability of tumor response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • LazertinibDrug

    Lazertinib will be administered orally.

  • AmivantamabDrug

    Amivantamab will be administered as an intravenous (IV) infusion.

  • CarboplatinDrug

    Carboplatin will be administered as IV infusion.

  • PemetrexedDrug

    Pemetrexed will be administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1)Time frame: Until the end of first cycle (21 days for Phase 1)
  2. Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1b)Time frame: Until the end of first cycle (28 days for Phase 1b)
  3. Overall Response Rate (ORR) (Phase 1b Expansion Cohorts A-D)Time frame: Up to 2.5 years
  4. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability (Phase 1b Expansion Cohorts A-E)Time frame: Up to 2.5 years
  5. Percentage of Participants with DLT (Phase 1b combination Lazertinib, Amivantamab, Platinum-doublet chemotherapy [LACP])Time frame: Until the end of first cycle (21 days for Phase 1b combination LACP)
  6. Number of Participants with AEs as a Measure of Safety and Tolerability (Phase 1b combination LACP)Time frame: Up to 2.5 years
  7. Overall Response Rate (ORR) per RECIST version 1.1 (v1.1) with NGS Analysis of Circulating Tumor ctDNA, IHC Analysis of EGFR and MET Expression (Phase 1b Expansion Cohort D)Time frame: Up to 2.5 years
  8. ORR Among Participants with MET3+ Staining on Greater Than or Equal to (>=)25 Percent (%) of Tumor Cells (Phase 1b Expansion Cohorts E and F)Time frame: Up to 2.5 years
  9. Duration of Response (DOR) Among Participants with MET3+ Staining on >=25% of Tumor Cells (Phase 1b Expansion Cohorts E and F)Time frame: Up to 2.5 years
  10. Clinical Benefit Rate (CBR) Among Participants with MET3+ Staining on >=25% of Tumor Cells (Phase 1b Expansion Cohorts E and F)Time frame: Up to 2.5 years

Locations

78 sites in 10 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • UCSF Helen Diller Comprehensive

    San Francisco, California

  • Stanford University Medical Center

    Stanford, California

  • Cedars Sinai Medical Center

    West Hollywood, California

  • H. Lee Moffitt Cancer & Research Institute

    Tampa, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University School Of Medicine

    St Louis, Missouri

  • Langone Health at NYC University, NYU School of Medicine

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Providence Portland Medical Center

    Portland, Oregon

  • University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Washington

    Seattle, Washington

  • Beijing Cancer Hospital

    Beijing, China

  • The First Bethune Hospital of Jilin University

    Changchun, China

  • Hunan Cancer hospital

    Changsha, China

  • West China School of Medicine/West China Hospital, Sichuan University

    Chengdu, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • The Fifth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Central Hospital of Jinan

    Jinan, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, China

  • Shanghai Chest Hospital

    Shanghai, China

  • Shengjing Hospital Of China Medical University

    Shenyang, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, China

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, China

  • Institut Bergonie

    Bordeaux, France

  • Centre Leon Berard

    Lyon, France

  • CHU de la Timone

    Marseille, France

  • Institut Curie

    Paris, France

  • CHU De Poitiers

    Poitiers, France

  • HIA Begin

    Saint-Mandé, France

  • Institut Gustave Roussy

    Villejuif, France

  • Evangelische Lungenklinik Berlin

    Berlin, Germany

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.